Table 1.
Baseline characteristics at SO therapy initiation
| Baseline characteristic | Study cohort (n = 258) |
|---|---|
| Age, years | 50.6±13.9 |
| Dialysis vintage, months | 29.3±27.5 |
| BMI, kg/m2 | 30.4±8 |
| Gender, male, n (%) | 143 (55.4) |
| Race, n (%) | |
| White | 160 (62.0) |
| African American | 64 (24.8) |
| Other | 34 (13.2) |
| Diabetes, n (%) | 121 (46.9) |
| Primary cause of ESRD, n (%) | |
| Diabetes mellitus | 90 (34.9) |
| Hypertension | 69 (26.7) |
| Glomerulonephritis | 47 (18.2) |
| Polycystic kidney disease | 10 (3.9) |
| Other | 34 (13.2) |
| Unknown | 8 (3.1) |
| Baseline PB dispensed through FreseniusRx | |
| No PB recorded, n (%) | 166 (64.3) |
| PB recorded in the FKC EHR database, n (%) | 110 (66.3) |
| PB recorded, n (%) | 92 (35.7) |
| Calcium acetate, n (%) | 19 (20.7) |
| Lanthanum carbonate, n (%) | 5 (5.4) |
| Sevelamer, n (%) | 58 (63.0) |
| >1 PB recorded, n (%) | 10 (10.8) |
| PD modality, n (%) | |
| Manual (CAPD) | 34 (13.2) |
| Automated (CCPD) | 196 (76) |
| Switched (CAPD to CCPD) | 28 (10.8) |
| Clinical parameters | |
| Serum phosphorus, mg/dL | 6.5±1.4 |
| Albumin-corrected calcium, mg/dL | 9.4±0.7 |
| Intact PTH, pg/mL | 459±317 |
| Serum albumin, g/dL | 3.7±0.4 |
| Kru, mL/min/1.73 m2 | 2.72±2.45 |
| PD Kt/V | 1.7±0.4 |
| Total Kt/V | 2.2±0.5 |
Values are expressed as mean ± SD, or n (%).
BMI, body mass index (kg/m2); CAPD, continuous ambulatory PD; CCPD, continuous cycling PD; Kru, residual urea clearance; FKC EHR, Fresenius Kidney Care Electronic Health Records; PB, phosphate binder; PD, peritoneal dialysis; PTH, parathyroid hormone; ESRD, end-stage renal disease.